Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
E For L Aim PCLBKK:EFORL-R 40 Cash-to-Debt is 0.07 as of Jun. 2026, which is 13% below its 10-year median of 0.08. GuruFocus rates BKK:EFORL-R with a GF Score™ of 40/100 and a GF Value™ of ฿0.14 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 120 Medical Distribution companies, E For L Aim PCL ranks worse than 89.17% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. E For L Aim PCL's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.07.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, E For L Aim PCLcouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for E For L Aim PCL's Cash-to-Debt or its related term are showing as below:
BKK:EFORL-R'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01 Med: 0.08 Max: 0.27
Current: 0.07
During the past 13 years, E For L Aim PCL's highest Cash to Debt Ratio was 0.27. The lowest was 0.01. And the median was 0.08.
BKK:EFORL-R's Cash-to-Debt is ranked worse than 89.17% of 120
companies
in the Medical Distribution industry
Industry Median: 0.56
vs BKK:EFORL-R: 0.07
E For L Aim PCL (BKK:EFORL-R) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
E For L Aim PCL Cash-to-Debt Related Terms
E For L Aim PCL Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for E For L Aim PCL's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
BKK:EFORL-R vs MCK, COR, CAH: Cash-to-Debt Comparison
For the Medical Distribution subindustry, E For L Aim PCL's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
E For L Aim PCL Cash-to-Debt vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, E For L Aim PCL's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where E For L Aim PCL's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
E For L Aim PCL (BKK:EFORL-R) has a Cash-to-Debt of 0.07 as of Jun. 2026. This is 13% below median its historical median of 0.08. Over the past decade, E For L Aim PCL's Cash-to-Debt has ranged from 0.01 to 0.27. According to the industry distribution chart, E For L Aim PCL ranks #107 out of 120 companies in the Medical Distribution industry, placing it in the top 89.2%.
Is E For L Aim PCL's Cash-to-Debt too high?
E For L Aim PCL's current Cash-to-Debt of 0.07 is 13% below median its 10-year median of 0.08. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.27. The Medical Distribution industry median Cash-to-Debt is 0.56. E For L Aim PCL's value of 0.07 is 87.5% below this industry median. Based on the distribution chart, E For L Aim PCL ranks #107 out of 120 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, E For L Aim PCL has a GF Score™ of 40/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does E For L Aim PCL's Cash-to-Debt compare to MCK and COR?
According to the Medical Distribution industry distribution chart, E For L Aim PCL ranks #107 out of 120 companies for Cash-to-Debt. This places E For L Aim PCL in the lower half of its industry. The industry median Cash-to-Debt is 0.56. E For L Aim PCL's value of 0.07 is 87.5% below this benchmark. Historically, E For L Aim PCL's own Cash-to-Debt has ranged from 0.01 to 0.27 over the past decade. While the company's 10-year median is 0.08 vs. the industry median of 0.56, E For L Aim PCL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Distribution company?
The median Cash-to-Debt among Medical Distribution companies is 0.56, based on 120 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. E For L Aim PCL's current Cash-to-Debt of 0.07 is 87.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Distribution industry, the median Cash-to-Debt is 0.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. E For L Aim PCL's current Cash-to-Debt is 0.07, which is 13% below median its own 10-year median of 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is E For L Aim PCL stock overvalued right now?
Based on GuruFocus' analysis, E For L Aim PCL (BKK:EFORL-R) is currently considered Modestly Undervalued. The stock's GF Value™ is ฿0.14, compared to a current price of ฿0.12 — trading 14.3% below its estimated fair value. The current Cash-to-Debt is 0.07, which is 13% below median its 10-year median of 0.08 and 87.5% below the Medical Distribution industry median of 0.56. E For L Aim PCL's overall GF Score™ is 40/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For E For L Aim PCL (BKK:EFORL-R), the current Cash-to-Debt is 0.07 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is E For L Aim PCL (BKK:EFORL-R) Overvalued in 2026?
Based on GuruFocus' analysis, E For L Aim PCL stock appears to be undervalued.
The current stock price of ฿0.12 is trading 14.3% below its estimated GF Value™ of ฿0.14.
GuruFocus considers E For L Aim PCL to be Modestly Undervalued.
Key valuation signals for BKK:EFORL-R:
Cash-to-Debt: 0.07 (13% below median its 10-year median of 0.08)
GF Value™: ฿0.14 vs. price of ฿0.12 (14.3% below fair value)
Industry Position: 87.5% below the Medical Distribution median (#107 of 120)
No single metric tells the full story. See the BKK:EFORL-R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
E For L Aim PCL is engaged in the distribution of medical devices and equipment. The company and subsidiary have distributor agreements for medical devices and equipment with foreign companies. Its products include Patient Monitor System, Central Monitors System, Defibrillator, Automated External Defibrillator (AED), Electrocardiographs, Electroencephalogram (EEG), PSG System (Sleep Labs), and Accessories and Consumables. The group is principally engaged in one operating segment which is the distribution of medical device and equipment and providing service of medical equipment. Their operations are carried out in Thailand.
40GF Score
Get the complete analysis for BKK:EFORL-R
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:EFORL-R has been successfully added to your 
